SYM FINANCIAL Corp Cuts Position in Alnylam Pharmaceuticals, Inc. $ALNY

SYM FINANCIAL Corp lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.9% in the second quarter, HoldingsChannel.com reports. The firm owned 944 shares of the biopharmaceutical company’s stock after selling 70 shares during the quarter. SYM FINANCIAL Corp’s holdings in Alnylam Pharmaceuticals were worth $308,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Bessemer Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 69 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $275,000. Strs Ohio purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $7,781,000. GAMMA Investing LLC increased its holdings in shares of Alnylam Pharmaceuticals by 14.3% in the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 77 shares in the last quarter. Finally, Brighton Jones LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $243,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $478.58 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The stock has a market capitalization of $62.73 billion, a P/E ratio of -193.76 and a beta of 0.36. The firm’s 50-day moving average is $459.70 and its two-hundred day moving average is $363.44. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. During the same period last year, the company earned ($0.13) EPS. The firm’s revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the sale, the executive vice president directly owned 25,231 shares of the company’s stock, valued at $11,405,673.55. This trade represents a 8.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Pushkal Garg sold 3,022 shares of the firm’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the sale, the executive vice president directly owned 20,221 shares in the company, valued at $9,129,377.08. This represents a 13.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,144 shares of company stock worth $44,160,261 over the last three months. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Truist Financial increased their price target on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the company a “buy” rating in a report on Friday, October 17th. Wolfe Research raised shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research note on Monday, August 4th. Barclays increased their price objective on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. JPMorgan Chase & Co. lowered their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a research note on Monday, October 13th. Finally, Oppenheimer raised shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price objective on the stock in a research note on Monday, August 4th. Twenty-three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $466.92.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.